Neurocrine Biosciences, Inc.
NBIXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeNeurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company carries a $16.19B market cap, placing it firmly in the large-cap category. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Market Cap
$16.19B
Beta
0.34
P/E (TTM)
24.77
P/E (Fwd)
12.67
EPS (TTM)
$6.50
EPS (Fwd)
$12.71
ROE
22.5%
ROA
11.6%
Cash
$1.32B
Total Debt
$463.5M
Free CF
$590.6M
52W Change
28.8%
Annual Financials
Cash vs Debt
Neurocrine Biosciences, Inc. holds $1.32B in cash against $463.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $590.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 22.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.6% further supports the picture of efficient asset utilization. Revenue has grown from $1.49B (2022) to $2.86B (2025), reflecting a 92% increase over the period.
With a beta below 0.7, Neurocrine Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, NBIX has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing NBIX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.